Amneal Pharmaceuticals LLC (labeler), 2021-08: Current FDA-approved U.S. mebendazole label. It gives the approved low-dose STH regimens, documents that plasma levels after 100 mg twice daily for three days stay at or below 0.03 mcg/mL, and states that a high-fat meal raises bioavailability.
Following administration of 100 mg twice daily for three consecutive days, plasma concentrations of EMVERM® (mebendazole) and its primary metabolite, the 2-amine hydrolyzed metabolite, do not exceed 0.03 mcg/mL and 0.09 mcg/mL, respectively. Dosing with a high fat meal increases the bioavailability of mebendazole
8
Amneal Pharmaceuticals LLC (labeler), 2021-08: Current FDA-approved U.S. mebendazole label. It gives the approved low-dose STH regimens, documents that plasma levels after 100 mg twice daily for three days stay at or below 0.03 mcg/mL, and states that a high-fat meal raises bioavailability. Label revised 8/2021; SPL version published on DailyMed 2026-09-24 (accessed 2026-11-20). Table 1 doses: 1 tablet (100 mg) once for pinworm; 1 tablet morning and evening for 3 consecutive days for whipworm, roundworm and hookworm. Also 5.2 Agranulocytosis/neutropenia 'at higher doses and for more prolonged durations'; 5.3 SJS/TEN with metronidazole; 10 Overdosage lists alopecia, reversible transaminase elevations, hepatitis, agranulocytosis, neutropenia, glomerulonephritis. Pregnancy 8.1: published literature 'has not reported a clear association' with major birth defects; animal data teratogenic at 10 mg/kg in rats. Emverm is an ANDA (073580) held by Amneal; the label carries no cimetidine or carbamazepine/phenytoin interaction text. Label PDF text extracted with pdftotext; quote checked against that extraction, page 8 of 15. Context: Emverm (Amneal, ANDA 073580) is the only mebendazole product still marketed in the U.S. (MBA-10/11). Also filed as MBD-21, MBA-12 (claims C1, C3, C5).
